Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Sep;69(3):633-51.
doi: 10.1007/s13105-013-0265-4. Epub 2013 Jun 22.

Role of omega-3 fatty acids in obesity, metabolic syndrome, and cardiovascular diseases: a review of the evidence

Silvia Lorente-Cebrián  1 , André G V Costa, Santiago Navas-Carretero, María Zabala, J Alfredo Martínez, María J Moreno-Aliaga
Affiliations
Review

Role of omega-3 fatty acids in obesity, metabolic syndrome, and cardiovascular diseases: a review of the evidence

Silvia Lorente-Cebrián et al. J Physiol Biochem. 2013 Sep.

Abstract

The present review aims to illustrate current knowledge about the efficacy of omega-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFAs) in treating/preventing several metabolic pathologies. We reviewed systematically the published evidence on the effectiveness of n-3 LC-PUFAs fish consumption or n-3 LC-PUFAs supplementation on prevention/treatment of obesity, metabolic syndrome, and cardiovascular diseases. Most of the reviewed studies were randomized-controlled interventional trials, although some relevant prospective and cross-sectional studies as well as some meta-analysis were also reviewed. Supplementation with n-3 LC-PUFAs might improve some obesity-associated metabolic syndrome features such as insulin resistance, hypertension and dyslipidemia by decreasing plasma triglycerides. Moreover, the blood pressure-lowering and anti-inflammatory properties of these fatty acids and their benefits in vascular function might confer cardioprotection. However, the efficacy of n-3 LC-PUFA on reducing myocardial infarction, arrhythmia, cardiac and sudden death, or stroke is controversial. Due to the beneficial actions of n-3 LC-PUFAs, several worldwide government and health organizations have established some recommendations of n-3 LC-PUFAs intake for groups of population. In general, the recommended levels for diseases prevention are lower than those advised for particular treatments. However, more clinical trials are necessary to recommend the most effective dosages and formulas (type of n-3 LC-PUFA, EPA/DHA ratio) for specific pathologies.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Am J Clin Nutr. 1997 May;65(5 Suppl):1645S-1654S - PubMed
    1. Haemostasis. 1979;8(3-5):227-33 - PubMed
    1. Am J Clin Nutr. 2007 Aug;86(2):324-33 - PubMed
    1. Am J Clin Nutr. 2002 Aug;76(2):326-30 - PubMed
    1. J Nutr Biochem. 2012 Sep;23(9):1192-200 - PubMed

Publication types

MeSH terms

Substances